(Q33980153)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Michael R Eyre

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Catherine Riney

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

Fabienne Brilot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Russell C Dale

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Lisa V Duffy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Marinka Twilt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Amy T Waldman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sona Narula

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Eyal Muscal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Erik Andersen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Despina Eleftheriou

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Paul A Brogan

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Rachel Kneen

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Gulay Alper

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Banu Anlar

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Evangeline Wassmer

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Kirsten Heineman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Cheryl Hemingway

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Andrew Kornberg

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Marc Tardieu

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Amber Stocco

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Brenda Banwell

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Mark P Gorman

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Susanne M Benseler

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ming Lim

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

11 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

142-150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

20 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Monoclonal antibodies and progressive multifocal leukoencephalopathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

The spectrum of neuromyelitis optica

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Tolerability and safety of rituximab (MabThera).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Acute ischemic stroke in children versus young adults

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117174

B cell depletion therapy for new-onset opsoclonus-myoclonus

29 October 2018

1 reference

12 December 2020

Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome

1 reference

12 December 2020

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

1 reference

12 December 2020

Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy

1 reference

12 December 2020

10.1212/WNL.0000000000000570

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24920861%20AND%20SRC:MED&resulttype=core&format=json